The information on this site is intended for healthcare professionals only
Healthcare Professionals
Payor Services
Making Dexcom rtCGM technology cost-effective for your practice or healthcare system
Discover payor information to support the mainstream adoption of life-changing real-time continuous glucose monitoring (rtCGM) technology into your local diabetes service.
NICE recommends wider access to diabetes technology
The latest NICE guidance asks HCPs to address the inequalities in access to CGM that exist. It recommends offering rtCGM or, in some cases, intermittent scanning CGM (isCGM) to all people with type 1 diabetes, and considering rtCGM for people with type 2 diabetes being treated with insulin.1–4
Type 1 diabetes in adults NICE guideline [NG17]
Offer adults with type 1 diabetes a choice of rtCGM or isCGM, based on their individual preferences, needs, characteristics, and the functionality of the devices available.1 (March 2022)
Diabetes (type 1 and type 2) in children and young people NICE guideline [NG18]
Offer rtCGM to all children and young people with type 1 diabetes, alongside education to support children and young people and their families and carers to use it (see recommendation 1.2.67). Offer isCGM if aged ≥4 years and clear preference is expressed or unable to use rtCGM.2 (March 2022)
Type 2 diabetes in adults NICE guideline [NG28]
Consider rtCGM as an alternative to isCGM for adults with insulin-treated type 2 diabetes if it is available for the same or lower cost.3 (June 2022)
Diabetes in pregnancy NICE guideline [NG3]
Offer rtCGM to all pregnant women with type 1 diabetes (offer isCGM if clear preference is expressed, or unable to use rtCGM), and consider rtCGM for pregnant women who are on insulin but do not have type 1 diabetes if they have problematic severe hypoglycaemia or unstable blood glucose levels that are causing concern despite efforts to optimise glycaemic control.4 (December 2020)
How will rtCGM impact your budget?
Dexcom has developed a CGM budget impact tool that you can use to predict the cost of implementing the NICE guidance and making sensor technology accessible for all eligible people with diabetes.
Acquisition cost vs long-term value
In the short term, Dexcom rtCGM use is associated with immediate and substantial reductions in rates of diabetes-related hospitalisation.5–8 Longer-term use can minimise the occurrence of diabetes-associated complications.9 A substantial body of clinical and health economic evidence demonstrates that Dexcom use generates savings that offset its acquisition cost, meaning the technology can (more than) pay for itself.9–11
Please contact us for further information or to request an appointment with a member of the Dexcom Market Access Team.
We would be happy to guide you through our budget impact model, cost offset data or services, and can also provide a Dexcom-specific budget impact model to estimate opportunity costs and service efficiencies for your health care system.
Discover how Dexcom rtCGM drives budget efficiencies rapidly
As any new technology evolves it tends to become less expensive. Dexcom rtCGM technology is now available at a significantly lower price than when initial cost effectiveness data was generated.9,11
Summarising cost-effectiveness in a healthcare intervention, incremental cost-effectiveness ratio (ICER) is often used in cost-effectiveness analyses. Recent ICER analyses show that, at annual cost of £925, Dexcom technology is likely to be cost saving over the long term in comparison to self-monitoring of blood glucose (SMBG) for people with type 1 and type 2 diabetes, driving service and cost efficiencies within months.9–11
1 Type 1 diabetes in adults: diagnosis and management. NICE guideline [NG17]. https://www.nice.org.uk/guidance/ng17.
2 Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE guideline [NG18]. https://www.nice.org.uk/guidance/ng18.
3 Type 2 diabetes in adults: management NICE guideline [NG28] https://www.nice.org.uk/guidance/ng28.
4 Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline [NG3]. https://www.nice.org.uk/guidance/ng3.
5 Heinemann L, et al. Lancet 2018;391:1367–77.
6 Mulinacci G, et al. Diabetes Technol Ther 2019;21(1):6–10.
7 CCG switch data. Dexcom data on file. 2021.
8 Bantry. Dexcom data on file. 2022.
9 Roze S, et al. Diabetes Care. 2020;43(10):2411–7.
10 Alshannaq H, et al. 58th Annual meeting of the EASD 19–23 September 2022.
11 Isitt J. et al. United Kingdom, Diabetes Ther, 2022;13(11–12):1875–90.
2 Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE guideline [NG18]. https://www.nice.org.uk/guidance/ng18.
3 Type 2 diabetes in adults: management NICE guideline [NG28] https://www.nice.org.uk/guidance/ng28.
4 Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline [NG3]. https://www.nice.org.uk/guidance/ng3.
5 Heinemann L, et al. Lancet 2018;391:1367–77.
6 Mulinacci G, et al. Diabetes Technol Ther 2019;21(1):6–10.
7 CCG switch data. Dexcom data on file. 2021.
8 Bantry. Dexcom data on file. 2022.
9 Roze S, et al. Diabetes Care. 2020;43(10):2411–7.
10 Alshannaq H, et al. 58th Annual meeting of the EASD 19–23 September 2022.
11 Isitt J. et al. United Kingdom, Diabetes Ther, 2022;13(11–12):1875–90.